Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 29Gemcitabine 16Cyclophosphamide 14Nivolumab 12Carboplatin 12Capecitabine 11Trastuzumab 9Paclitaxel 9Magnetic Resonance Spectroscopy 8Irinotecan 8Bevacizumab 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8olaparib 7fludarabine 7Docetaxel 7spartalizumab 6aldesleukin 6Drug Therapy 6Cisplatin 6durvalumab 5atezolizumab 5Standard of Care 5Specimen Handling 5Oxaliplatin 5Biopsy 5sargramostim 4palbociclib 4niraparib 4enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × daratumumab × Breast × Clear all
NCT03098550 2021-07-23

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
105 enrolled 21 charts
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡